top of page
Meningococcal Vaccine group A&C

Generic Name: 

Meningococcal Vaccine group A&C


Meningococcal disease is an infection caused by a strain of bacteria called meningococcus. This invasive bacterium is the leading cause of bacterial meningitis in middle-aged children.

Vaccination is recommended for areas with endemic transmission, travelers to countries with epidemic meningococcal disease, family or agency contacts, and military recruits.

It is also recommended for subjects living in closed communities and in close contact with meningococcal group A and C patients/carriers.

Meningococcal disease may include meningitis (a severe and potentially life-threatening inflammation of the membranes lining the brain and spinal cord) and/or life-threatening blood infections. Meningococcal disease can cause loss of limbs through amputation, hearing loss, nervous system problems, intellectual disability, seizures, and stroke.


Each dose (0.5ml) of vaccine contains:

Purified Polysaccharide of Neisseria meningitidis

Meningococcal Vaccine group A&C-Biovex.jpeg
Meningococcal Vaccine group A&C

Pharmaceutical Form:

FreezLyophilisate powder


Method of Administration:

Administer the vaccine by intramuscular or subcutaneous route.



0.5 ml per administration


  • One dose in glass vial with diluent and disposable syringe.

  • Ten dose in glass vial with diluent.

Possible Side Effects:

Reactions to vaccination usually consist of local injection site reactions (pain, redness), transient high fever, headache, and vomiting in children.


This may include hypersensitivity to any of the vaccine components. Ongoing acute or chronic illness like fever, severe infection, persistent Diarrhoea, vomiting.

Shelf Life:

Product is good to use for 24 months from the date of manufacture.



Store at +2° C to +8° C.

bottom of page